SUNNYVALE, Calif., May 11, 2017 /PRNewswire/ -- Accuray Incorporated
(NASDAQ: ARAY) announced today that studies continue to demonstrate
the unmatched flexibility of the cutting-edge TomoTherapy® System
to treat, with precision and efficiency, a wide variety of
indications of all complexities. More than 50 studies were
presented during poster and oral sessions at the 36th
Annual European Society for Radiotherapy & Oncology (ESTRO)
Meeting in Vienna, Austria,
May 5 - 9, 2017.
Study highlights include:
Breast
- A study evaluated hypofractionated intensity-modulated
radiation therapy (IMRT) using TomoHelical™ in 121 postmastectomy
patients with implant-based immediate breast reconstruction (IBR).
Results demonstrated the TomoTherapy Treatment Planning System
produced high-quality treatment plans providing optimal coverage of
both the chest wall and supraclavicular region and sparing of all
organs at risk. An additional analysis showed that the superior
dosimetric outcomes provided treatment benefits. The side effect
profile following treatment was favorable, with no patient
experiencing greater than grade 2 acute toxicity. Rates of
toxicity remained low in 85 patients with a median follow-up of
14.2 months. Clinicians at the European Institute of Oncology in
Milan, Italy, conducted these two
studies.
Lung
- A study of 68 patients with medically inoperable lung tumors
found that image-guided stereotactic body radiation therapy (SBRT)
delivered using TomoHelical provides an effective treatment option
with minimal toxicity. The study was conducted at three Italian
hospitals.
Prostate
- A retrospective study evaluated the safety and efficacy of
preoperative TomoHelical in combination with chemotherapy in
patients with locally advanced rectal cancer (LARC). The three-year
local control rate was 96.9% and treatment was well-tolerated.
Clinicians at two Swiss hospitals conducted the research, which
included the largest of this patient population to date.
- Toxicity and survival outcomes were reported for patients with
high-risk prostate cancer enrolled in a phase 1-2 study evaluating
hypofractionated TomoTherapy® and routine irradiation of pelvic
lymph nodes. Five- and seven-year biochemical relapse-free survival
(bRFS) was 87% and 80%, respectively; cancer-specific survival was
98% and 96%. Treatment was well-tolerated. Clinicians at the San
Raffaele Scientific Institute in Milano,
Italy conducted the study.
- Researchers at three European centers assessed the feasibility
of boosting radiation dose to the dominant intraprostatic lesion
(DIL) using the TomoTherapy System and found it to be a viable
treatment option. Additionally, based on a dosimetric comparison of
treatment plans, the system performed better than volumetric
modulated arc radiotherapy (VMAT) in terms of achievable boost
doses, target coverage and organ at risk sparing, and was similar
in several aspects to intensity-modulated proton therapy
(IMPT).
"The data presented at the ESTRO 36 meeting continue to show
that the benefits of the TomoTherapy® System's ring gantry platform
and daily 3D image guidance in the treatment of a range of
clinical indications." said Fabienne Hirigoyenberry, VP Global
Medical and Scientific Affairs of Accuray. "The Radixact™ System,
the latest generation TomoTherapy platform, provides the same
unrivaled delivery capabilities while giving clinicians the
versatility to treat the broad spectrum of patients and disease
types with the highest level of precision and increased speed and
efficiency."
About Accuray
Accuray Incorporated (NASDAQ: ARAY) is a radiation oncology company
that develops, manufactures, and sells precise, innovative tumor
treatment solutions that set the standard of care with the aim of
helping patients live longer, better lives. The company's
leading-edge technologies deliver the full range of radiation
therapy and radiosurgery treatments. For more information, please
visit www.accuray.com.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to clinical applications,
clinical results, patient outcomes and Accuray's leadership
position in radiation oncology innovation and technologies.
Forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially from
expectations, including but not limited to the risks detailed from
time to time under the heading "Risk Factors" in the company's
report on Form 10-K, filed on August 24,
2016, the company's reports on Form 10-Q, filed on
November 1, 2016, February 3, 2017, and May
5, 2017, and as updated periodically with the company's
other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to
Accuray at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
Media Contacts:
Beth Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
bkaplan@accuray.com
Jane Hauser
MSLGROUP
+1 (781) 684-0770
accuray@mslgroup.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/new-data-reinforce-benefits-of-tomotherapy-platform-for-mainstream-radiation-therapy-treatment-indications-300455781.html
SOURCE Accuray Incorporated